Patents Assigned to deCODE genetics ehf.
  • Publication number: 20170191134
    Abstract: Certain sequence variants have been found to be useful for correcting Prostate Specific Antigen levels in humans. The invention provides diagnostic applications based on such correction, including methods of diagnosis of prostate cancer.
    Type: Application
    Filed: August 8, 2016
    Publication date: July 6, 2017
    Applicant: deCODE genetics ehf
    Inventors: Julius Gudmundsson, Daniel Gudbjartsson, Patrick Sulem
  • Patent number: 8951735
    Abstract: The invention pertains to certain genetic variants that have been determined to be susceptibility variants of breast cancer. Methods of disease management, including diagnosing increased susceptibility to breast cancer, methods of predicting response to therapy and methods of predicting prognosis using such variants are described. The invention further relates to kits useful in the methods of the invention.
    Type: Grant
    Filed: July 3, 2009
    Date of Patent: February 10, 2015
    Assignee: deCODE Genetics ehf.
    Inventors: Simon Stacey, Patrick Sulem
  • Patent number: 8865400
    Abstract: The present invention is characterized by certain genetic variants being susceptibility variants for prostate cancer. The invention relates to methods of determining increased susceptibility to prostate cancer, as well as methods of determining decreased susceptibility to prostate cancer, using such variants. The invention further relates to kits for determining a susceptibility to prostate cancer.
    Type: Grant
    Filed: February 7, 2008
    Date of Patent: October 21, 2014
    Assignee: deCODE Genetics ehf.
    Inventors: Julius Gudmundsson, Patrick Sulem
  • Publication number: 20140275553
    Abstract: The invention relates to substituted benzothiazoles, benzoxazoles—and their counterparts having pyridine and pyrimidine rings replacing the benzene ring—that are PDE4 inhibitors useful for treating stroke, myocardial infarct, and cardiovascular inflammatory conditions, to pharmaceutical compositions comprising these compounds, and to methods for the treatment of stroke, myocardial infarct, and cardiovascular inflammatory conditions in a mammal. The compounds have general formula I: in which A and B are carbocycles or heterocycles.
    Type: Application
    Filed: May 28, 2014
    Publication date: September 18, 2014
    Applicant: deCODE genetics ehf
    Inventors: Jasbir SINGH, Mark E. GURNEY, Alex BURGIN, Alexander KISELYOV, Munagala RAO
  • Patent number: 8828657
    Abstract: The present invention discloses certain genetic variants as susceptibility variants for lung cancer. The invention relates to methods of risk assessment using such variants. The invention further relates to kits for use in risk assessment of lung cancer.
    Type: Grant
    Filed: February 16, 2009
    Date of Patent: September 9, 2014
    Assignee: deCODE Genetics ehf.
    Inventors: Thorunn Rafnar, Thorgeir E. Thorgeirsson, Patrick Sulem, Frank Geller
  • Publication number: 20140248615
    Abstract: It has been discovered that certain polymorphic markers on chromosome 6 and chromosome 11 are indicative of a susceptibility to prostate cancer and colon cancer. The invention describes diagnostic applications for determining a susceptibility to cancer using such markers, as well as kits for use in such applications.
    Type: Application
    Filed: March 6, 2014
    Publication date: September 4, 2014
    Applicant: deCODE Genetics ehf.
    Inventors: Steinunn Thorlacius, Patrick Sulem, Julius Gudmundsson
  • Patent number: 8808985
    Abstract: The present invention discloses certain genetic variants as susceptibility variants for peripheral arterial disease (PAD) and abdominal aortic aneurysm (AAA). The invention relates to risk management using such variants. The invention further relates to kits for use in risk assessment of PAD and AAA.
    Type: Grant
    Filed: April 1, 2009
    Date of Patent: August 19, 2014
    Assignee: deCODE Genetics ehf.
    Inventors: Thorgeir Thorgeirsson, Patrick Sulem, Frank Geller, Kristinn P. Magnusson
  • Publication number: 20140227693
    Abstract: The invention relates to procedure and methods of determining a susceptibility to cardiac arrhythmia, including Atrial Fibrillation, Atrial Flutter and Stroke, by assessing the presence or absence of alleles at polymorphic markers found to be associated with Atrial Fibrillation, Atrial Flutter and Stroke. The invention further relates to kits encompassing reagents for assessing such markers, and diagnostic methods, uses and procedures for utilizing such susceptibility markers.
    Type: Application
    Filed: January 13, 2014
    Publication date: August 14, 2014
    Applicant: deCODE Genetics ehf.
    Inventors: Anna Helgadottir, Daniel Gudbjartsson
  • Patent number: 8795963
    Abstract: The invention relates to procedures and methods of determining a susceptibility to cardiac arrhythmia, including Atrial Fibrillation, Atrial Flutter and Stroke, by assessing the presence or absence of alleles at polymorphic markers found to be associated with risk of these conditions. The invention further relates to kits encompassing reagents for assessing such markers, and diagnostic methods, uses and procedures for utilizing such susceptibility markers.
    Type: Grant
    Filed: March 30, 2010
    Date of Patent: August 5, 2014
    Assignee: deCODE Genetics ehf.
    Inventors: Hilma Holm, Daniel Gudbjartsson
  • Patent number: 8796182
    Abstract: The invention relates to variants that predispose to risk of type 2 diabetes, basal cell carcinoma and breast cancer. It has been discovered that certain genetic variants confer risk of these diseases when inherited from one parent, but not the other. The invention provides methods of disease management, including diagnostic methods, utilizing such parental origin effects.
    Type: Grant
    Filed: July 9, 2010
    Date of Patent: August 5, 2014
    Assignee: deCODE Genetics ehf.
    Inventors: Valgerdur Steinthorsdottir, Gudmar Thorleifsson, Daniel Gudbjartsson, Gisli Masson, Augustine Kong
  • Publication number: 20140179546
    Abstract: The invention pertains to certain genetic variants on Chr5p12 and Chr10q26 as susceptibility variants of breast cancer. Methods of disease management, including diagnosing increased and/or decreased susceptibility to breast cancer, methods of predicting response to therapy and methods of predicting prognosis using such variants are described. The invention further relates to kits useful in the methods of the invention.
    Type: Application
    Filed: October 9, 2013
    Publication date: June 26, 2014
    Applicant: deCODE Genetics ehf.
    Inventors: Simon Stacey, Patrick Sulem, Andrei Manolescu
  • Patent number: 8697360
    Abstract: It has been discovered that certain polymorphic markers on chromosome 6 and chromosome 11 are indicative of a susceptibility to prostate cancer and colon cancer. The invention describes diagnostic applications for determining a susceptibility to cancer using such markers, as well as kits for use in such applications.
    Type: Grant
    Filed: November 26, 2008
    Date of Patent: April 15, 2014
    Assignee: deCODE Genetics ehf.
    Inventors: Steinunn Thorlacius, Patrick Sulem, Julius Gudmundsson
  • Publication number: 20140087961
    Abstract: The invention discloses genetic variants that have been determined to be susceptibility variants of thyroid cancer. Methods of disease management, including methods of determining susceptibility to thyroid cancer, methods of predicting response to therapy and methods of predicting prognosis of thyroid cancer using such variants are described. The invention further relates to kits useful in the methods of the invention.
    Type: Application
    Filed: March 16, 2012
    Publication date: March 27, 2014
    Applicants: ILLUMINA INC., deCODE Genetics ehf.
    Inventors: Patrick Sulem, Julius Gudmundsson
  • Publication number: 20140080727
    Abstract: Markers on chromosome 19q13, in particular, markers in the ALDH16A1 gene, are associated with risk of gout in humans. Diagnostic applications using the markers, such as determining the susceptibility to Gout, are described.
    Type: Application
    Filed: February 9, 2012
    Publication date: March 20, 2014
    Applicants: Illumina Inc., deCODE Genetics ehf.
    Inventor: Patrick Sulem
  • Patent number: 8637244
    Abstract: The invention relates to procedure and methods of determining a susceptibility to cardiac arrhythmia, including Atrial Fibrillation, Atrial Flutter and Stroke, by assessing the presence or absence of alleles at polymorphic markers found to be associated with Atrial Fibrillation, Atrial Flutter and Stroke. The invention further relates to kits encompassing reagents for assessing such markers, and diagnostic methods, uses and procedures for utilizing such susceptibility markers.
    Type: Grant
    Filed: December 5, 2007
    Date of Patent: January 28, 2014
    Assignee: deCODE Genetics ehf.
    Inventors: Anna Helgadottir, Daniel Gudbjartsson
  • Publication number: 20130338012
    Abstract: It has been found that certain alleles of the human MYH6 gene are predictive of risk of certain conditions, including Sick Sinus Syndrome, Atrial Fibrillation, Pacemaker implantation and Thoracic aortic aneurysm, in humans. The invention provides diagnostic applications using such alleles, including methods of determining a susceptibility of Sick Sinus Syndrome and related conditions.
    Type: Application
    Filed: November 17, 2011
    Publication date: December 19, 2013
    Applicants: ILLUMINA INC., deCODE Genetics ehf.
    Inventors: Patrick Sulem, Hilma Holm, Daniel Gudbjartsson
  • Patent number: 8580501
    Abstract: The invention pertains to certain genetic variants on Chr5p12 and Chr10q26 as susceptibility variants of breast cancer. Methods of disease management, including diagnosing increased and/or decreased susceptibility to breast cancer, methods of predicting response to therapy and methods of predicting prognosis using such variants are described. The invention further relates to kits useful in the methods of the invention.
    Type: Grant
    Filed: May 21, 2008
    Date of Patent: November 12, 2013
    Assignee: deCODE Genetics ehf.
    Inventors: Simon Stacey, Patrick Sulem, Andrei Manolescu
  • Publication number: 20130296175
    Abstract: Polymorphic variants that have been found to be associated with risk of urinary bladder cancer are provided herein. Such polymorphic markers are useful for diagnostic purposes, such as in methods of determining a susceptibility, and for prognostic purposes, including methods of predicting prognosis and methods of assessing an individual for probability of a response to therapeutic 5 agents, as further described herein. Further applications utilize the polymorphic markers of the invention include screening and genotyping methods. The invention furthermore provides related kits, and computer-readable media and apparatus.
    Type: Application
    Filed: January 12, 2012
    Publication date: November 7, 2013
    Applicants: ILLUMINA INC., deCODE Genetics ehf.
    Inventors: Thorunn Rafnar, Patrick Sulem
  • Publication number: 20130273543
    Abstract: The invention discloses genetic variants that have been determined to be susceptibility variants of thyroid cancer. Methods of disease management, including methods of determining susceptibility to thyroid cancer, methods of predicting response to therapy and methods of predicting prognosis of thyroid cancer using such variants are described. The invention further relates to kits useful in the methods of the invention.
    Type: Application
    Filed: December 20, 2011
    Publication date: October 17, 2013
    Applicant: deCODE Genetics ehf.
    Inventors: Julius Gudmundsson, Patrick Sulem
  • Publication number: 20130253847
    Abstract: Polymorphic variants (e.g., certain alleles of polymorphic markers) that have been found to be associated with high blood eosinophil counts, conditions causative of eosinophilia (e.g., asthma, myocardial infarction), and/or hypertension are provided herein. Such polymorphic markers are useful for diagnostic purposes, such as in methods of determining a susceptility, and for prognostic purposes, including methods of predicting prognosis and methods of assessing an individual for probability of a response to a therapeutic agent, as further described herein. Further applications utilize the polymorphic markers of the invention include, screening methods and genotyping methods. The invention furthermore provides related kits, computer-readable medium, and apparatus.
    Type: Application
    Filed: December 20, 2012
    Publication date: September 26, 2013
    Applicant: deCODE Genetics ehf.
    Inventors: Daniel Gudbjartsson, Unnur Steina Bjornsdottir, Patrick Sulem